Toward the Mutational Landscape of Autosomal Dominant Retinitis Pigmentosa: A Comprehensive Analysis of 258 Spanish Families

Size: px
Start display at page:

Download "Toward the Mutational Landscape of Autosomal Dominant Retinitis Pigmentosa: A Comprehensive Analysis of 258 Spanish Families"

Transcription

1 Genetics Toward the Mutational Landscape of Autosomal Dominant Retinitis Pigmentosa: A Comprehensive Analysis of 258 Spanish Families Inmaculada Martin-Merida, 1,2 Domingo Aguilera-Garcia, 1 Patricia Fernandez-San Jose, 1,2 Fiona Blanco-Kelly, 1,2 Olga Zurita, 1,2 Berta Almoguera, 1,3 Blanca Garcia-Sandoval, 4 Almudena Avila-Fernandez, 1,2 Ana Arteche, 1 Pablo Minguez, 1 Miguel Carballo, 5 Marta Corton, 1,2 and Carmen Ayuso 1,2 1 Department of Genetics, Instituto de Investigación Sanitaria Fundación Jiménez Díaz University Hospital Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain 2 Center for Biomedical Network Research on Rare Diseases (CIBERER), ISCIII, Madrid, Spain 3 Center for Applied Genomics, Children s Hospital of Philadelphia, Philadelphia, Pennsylvania, United States 4 Department of Ophthalmology, Instituto de Investigación Sanitaria Fundación Jiménez Díaz University Hospital Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain 5 Molecular Genetics Unit, Hospital de Terrassa, Terrassa, Barcelona, Spain Correspondence: Carmen Ayuso, Servicio de Genética, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Av. Reyes Católicos, 2. Madrid, Spain; cayuso@fjd.es. MCo and CA contributed equally to the work presented here and should therefore be regarded as equivalent authors. Submitted: January 11, 2018 Accepted: April 6, 2018 Citation: Martin-Merida I, Aguilera- Garcia D, Fernandez-San Jose P, et al. Toward the mutational landscape of autosomal dominant retinitis pigmentosa: a comprehensive analysis of 258 Spanish families. Invest Ophthalmol Vis Sci. 2018;59: doi.org/ /iovs PURPOSE. To provide a comprehensive overview of the molecular basis of autosomal dominant retinitis pigmentosa (adrp) in Spanish families. Thus, we established the molecular characterization rate, gene prevalence, and mutational spectrum in the largest European cohort reported to date. METHODS. A total of 258 unrelated Spanish families with a clinical diagnosis of RP and suspected autosomal dominant inheritance were included. Clinical diagnosis was based on complete ophthalmologic examination and family history. Retrospective and prospective analysis of Spanish adrp families was carried out using a combined strategy consisting of classic genetic techniques and next-generation sequencing (NGS) for single-nucleotide variants and copy number variation (CNV) screening. RESULTS. Overall, 60% of our families were genetically solved. Interestingly, 3.1% of the cohort carried pathogenic CNVs. Disease-causing variants were found in an autosomal dominant gene in 55% of the families; however, X-linked and autosomal recessive forms were also identified in 3% and 2%, respectively. Four genes (RHO, PRPF31, RP1, and PRPH2) explained up to 62% of the solved families. Missense changes were most frequently found in adrpassociated genes; however, CNVs represented a relevant disease cause in PRPF31- and CRXassociated forms. CONCLUSIONS. Implementation of NGS technologies in the adrp study clearly increased the diagnostic yield compared with classic approaches. Our study outcome expands the spectrum of disease-causing variants, provides accurate data on mutation gene prevalence, and highlights the implication of CNVs as important contributors to adrp etiology. Keywords: adrp, NGS, CNV, mutation gene prevalence, characterization rate Retinitis pigmentosa (RP) is the most prevalent form of inherited retinal dystrophy (IRD), with an overall prevalence of 1: RP is characterized by primary degeneration and death of rod photoreceptor cells followed by secondary loss of cone photoreceptors. 2 Symptoms usually start with night blindness, followed by progressive restriction of the peripheral visual field, culminating in progressive visual acuity loss. 1 Ophthalmological examination shows pigment deposits typically seen as bone spicules in the peripheral retina, attenuation of blood vessels, and waxy pallor of the optic disc evidenced on slit-lamp examination of the eye fundus, and diminished or even nonrecordable signals on ERG. 1,3 However, clinical features, disease onset, and progression may vary significantly between patients, even those belonging to the same family. 2 RP is characterized by its extreme genetic heterogeneity, with all inheritance patterns described. 3 Autosomal dominant RP (adrp) accounts for approximately 15% of Spanish RP families. 4 Currently, adrp-causing variants have been described in 28 genes (in the public domain, sum-dis.htm#b-diseases), with incomplete penetrance reported in some specific genes. 5 Given the underlying complexity of adrp, identifying its genetic basis is a challenging task, although one that may not only aid in clinical diagnosis and counseling, but also contribute to the development of future gene-based therapies. Copyright 2018 The Authors iovs.arvojournals.org j ISSN: This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

2 Comprehensive Genetic Analysis of Spanish adrp Families IOVS j May 2018 j Vol. 59 j No. 6 j 2346 TABLE 1. Molecular Strategy Used in Our Cohort of Spanish Patients With adrp The table shows the number of families characterized versus number of families screened using each technology. In bold: number of families characterized including the eight CNVs found by MLPA or NGS. * Classical techniques: SSCP/DGGE/Sanger and/or genotyping microarray. Naïve families screened by classical techniques. Non-naïve families in whom NGS was performed using a gene panel and/or WES. TruSightOne Sequencing Panel in naïve families (not prescreened). Different molecular approaches, such as indirect screening methods and genotyping microarrays, have been developed to improve the genetic testing of adrp. 6,7 However, these costly and laborious techniques cannot address the full spectrum of disease-causing variants, thus leading to low diagnostic rates. Nowadays, next-generation sequencing (NGS), mainly gene panel based strategies, represents the primary first-tier approach for all forms of IRD, yielding higher diagnostic rates. 8 The application of NGS in patients with IRD allows for a hypothesis-free analysis of the genes involved, regardless of the phenotype or inheritance pattern Although NGS is expected to increase diagnostic rates in adrp, 8 only the exhaustive analysis of a large cohort of American patients has been reported 5 ; therefore, the actual performance of NGS on adrp forms has not been yet fully explored. Copy number variants (CNVs) also play a substantial role in adrp 12 and could explain, at least partially, some of the missing heritability associated with adrp. Recently, it has been demonstrated the capability to detect CNVs by read-depth strategies using NGS data sets. 13 However, the exact contribution of CNVs in adrp remains largely unknown due to lack of comprehensive screening in most of the NGS studies. In this work, we provide a comprehensive overview of the molecular basis and mutational spectrum of adrp in the largest cohort of European origin reported to date, comprising Spanish families, using different genetic approaches, including NGS and CNV screening. SUBJECTS AND METHODS Cohort Description All subjects were selected by reviewing the database of IRD patients at Fundación Jiménez Díaz University Hospital (FJD, Madrid, Spain), spanning 27 years of collected data. The adrp cohort includes 258 unrelated Spanish families with clinical diagnosis of RP reached after a complete ophthalmologic examination 4,14 and at least two consecutive affected generations. Informed consent was signed by all the participating subjects. DNA samples were collected from the FJD Biobank. This study was reviewed and approved by the Ethics Committee of our hospital, according to the tenets of the Declaration of Helsinki and subsequent revisions. Mutational Screening of Single-Nucleotide Variants (SNVs) Different genetic tools were used over time as first-tier diagnostic approach (Table 1): (1) a classical algorithm based on screening of the most prevalent adrp-associated genes by single-strand conformation polymorphism (SSCP), CG-clamped denaturing gradient gel electrophoresis (DGGE), 6 Sanger sequencing, and/or commercial Arrayed Primer Extension (APEX)-based genotyping microarrays (Asper Biotech, Tartu, Estonia) to detect previously known mutations in adrp genes 7 ; and (2) targeted NGS of 74 IRD-associated genes (Supplementary Table S1) using the TruSightOne Sequencing Panel (Illumina, San Diego, CA, USA). This targeted clinical exome captures 12 Mb of genomic sequence enriched for 62,000 exons, spanning 4813 genes associated with known inherited diseases in Online Mendelian Inheritance in Man (in the public domain, and Human Gene Mutation Database (HGMD; in the public domain, hgmd.cf.ac.uk). Only coding exons and 10 bp of flanking 5 0 and 3 0 intronic sequence were covered with this approach. Libraries were prepared according to the manufacturer s instructions and sequenced in groups of 24 samples on the NextSeq500 platform (Illumina) using the NextSeq HighOutput kit. Bioinformatic analysis was performed using the online platform BaseSpace (Illumina) and, subsequently, variant annotation and prioritization was made with the VariantStudio software (Illumina). During this analysis, potentially pathogenic variants were prioritized in a subpanel of 74 IRD-associated genes. A total of 105 index cases uncharacterized with the classical algorithm were further analyzed by NGS using custom gene panels or whole-exome sequencing (WES), as previously reported. 8,15,16 Pathogenicity of variants was established according to their allele frequency in gnomad (in the public domain, gnomad.broadinstitute.org/), in silico prediction tools for novel splicing and missense variants as implemented in the commercial Alamut software (Interactive Biosoftware, Rouen, France), and segregation in the family when other relatives were available. 8 Besides, all the variants were also manually checked in HGMD and ClinVar databases (in the public domain, and in the

3 Comprehensive Genetic Analysis of Spanish adrp Families IOVS j May 2018 j Vol. 59 j No. 6 j 2347 literature. All identified variants classified as pathogenic or likely to be pathogenic were confirmed by Sanger sequencing. CNV Analysis CNV analysis of adrp-associated genes was performed using two different approaches. First, Multiplex Ligation-dependent Probe Amplification (MLPA) using the P235 kit (MRC-Holland, Amsterdam, The Netherlands) was conducted in 103 uncharacterized families after classical approach or custom NGS gene panel. 12 Additionally, in the cases with NGS data available, we applied the open source CoNVading software (Copy Number Variation Detection In Next-Generation Sequencing Gene Panels, in the public domain, molgenis-pipelines/content/convading/convading.html), which uses a read-depth strategy that is capable of identifying CNVs at the exon level. Default parameters were used. Final results were obtained for each sample after manual and bioinformatics data curation. Further validation of positive CNV calls was carried out by MLPA using the P235 or P221 kit. CNVs were further delimited by array-based comparative genomic hybridization (acgh). 12 In cases of CRX deletions, a commercial or a customized 60K acgh was performed (Agilent Technologies Inc, Santa Clara, CA, USA). Haplotype Analysis Three microsatellite markers with high heterozygosity (D19S606, D19S596, and D19S879) flanking 1.5 Mb the CRX gene and an intragenic polymorphic marker (D19S902) were analyzed in two families with apparently the same causative variant to determine a possible common ancestor. RESULTS Mutation Detection Rate The overall diagnostic detection rate in our Spanish adrp cohort was 60% (155/258) after applying sequential SNV and CNV screening over the past 27 years. Overall, our families have been analyzed using several molecular approaches, each obtaining different molecular diagnostic yields (Table 1): a classical approach in 226 families, NGS in 32 families, or both approaches in 105 families. The diagnostic rate has clearly increased over time with the implementation of new highthroughput approaches, from approximately 38% (87/226) obtained with classical molecular screening to 66% (21/32) of current characterization yield for naïve patients analyzed by NGS, the first-tier approach used since Additionally, NGS analysis allowed us to characterize 47 of 105 retrospective negative adrp cases. More specifically, disease-causing variants were detected by the following: initial direct (Sanger) or indirect (SSCP/DGGE) screening of the most prevalent genes in 46 families; screening of known mutations through an adrp mutation chip in 41 families; NGS in 60 cases; and MLPA or CNV analysis in 8 families. A total of 103 (40%) families remain unsolved; however, 34 of them could not be analyzed by the most recent NGS studies. Mutational Spectrum Our cohort showed high allelic and genetic heterogeneity. A total of 114 different, likely causal SNVs and CNVs were found (Tables 2, 3). Fifty-three of them have been identified in our adrp cohort for the first time. Eighteen variants showed recurrence in two families, and only seven variants in the RHO, NR2E3, C1QTNF5, and PRPF3 genes can be considered as common, being present in three or more unrelated families and accounting for 13.6% (35/258) of the families (Supplementary Table S2). The most prevalent mutations seen in our cohort were p.(pro347leu) in the RHO gene, followed by p.(gly56arg) in the NR2E3 gene. Mutations in 26 different genes were identified in our study (Table 4): 17 adrp-related genes in 138 families (53.5%), 1 autosomal dominant late-onset retinal degeneration gene in 4 different families (1.6%), 3 X-linked RP associated genes in 8 families (3.1%), and 5 different autosomal recessive IRDassociated genes in 5 families (1.9%). Pedigree and segregation analysis for these reclassified families are shown in Supplementary Figure S1. Four adrp-associated genes accounted for 62% (96/155) of the characterized families, with RHO being the most prevalent gene, followed by PRPF31, RP1, and PRPH2. In general, most of the adrp-associated causal variants were missense, except for PRPF31, RP1, CRX, and TOPORS, in which loss-of-function variants were the most prevalent (Table 4). Copy Number Variation We identified eight CNVs affecting three different adrp genes in seven unrelated families (Table 3) using a combination of MLPA and bioinformatic analysis of NGS data. The prevalence of CNVs in our adrp cohort was 3.1% (8/258), and this type of mutational event accounted for 5% (8/160) of all the identified variants. PRPF31 had the highest prevalence of CNVs in our series, with five different variations identified in four families (1.9%: 5/ 258), including two contiguous gene deletions, two partial deletions involving a single exon, and one partial multi-exon duplication. In a particularly noteworthy finding, we report a novel partial deletion spanning exon 9 in family RP-0076 identified using NGS data (Fig.); all remaining deletions have been previously described. 12 A partial deletion in the CRX gene encompassing exons 3 and 4 was identified in two adrp families (RP-1092 and RP- 1192) by NGS (Fig.). Further MLPA and acgh analysis allowed us to confirm, segregate, and refine descriptions of these deletions. Both probands had an overlapping genomic region spanning from intron 2 to the 3 0 untranslated region of CRX; however, we could not delimit the exact breakpoints. No other genes were involved in the distal 3 0 region of either deletion. Haplotype analysis ruled out a possible founder effect for this CNV (Supplementary Figure S2). Clinical and Genetic Reclassification of X-linked and Recessive Families NGS analysis revealed that 13 families (5%) had been misclassified as autosomal dominant (Supplementary Figure S1). A closer analysis of these families showed likely diseasecausing X-linked variants in RPGR (four families), RP2 (two families), and CHM (two families). Similarly, we identified biallelic pathogenic variants compatible with autosomal recessive inheritance in five families, including a homozygous splice-site variant in EYS, and compound heterozygous variants for ABCA4, CNGA1, RDH5, and USH2A. The families carrying the RDH5 and USH2A variants were only partially solved and, to date, additional variants explaining pseudo-dominant inheritance have not yet been identified. Ophthalmologic reevaluation was performed in those recessive cases in which the respective genes were associated with a clinical diagnosis other than RP. In the RDH5 case, the proband had night blindness, nonrecordable scotopic ERG, normal disc and retina vessels, small white dots in the midperiphery to the posterior pole, and no macular involve-

4 Comprehensive Genetic Analysis of Spanish adrp Families IOVS j May 2018 j Vol. 59 j No. 6 j 2348 TABLE 2. Spectrum of Likely Pathogenic SNVs Identified in Our Cohort of 258 adrp Spanish Families Gene Exon Nucleotide Change Protein Change No. Families Reference BEST1 6 c.682g>a p.(asp228asn) 2 Davidson, CRX 3 c.122g>a p.(arg41gln) 1 Swain, CRX 4 c.429del p.(pro145leufs*42) 1 This study CRX 4 c.590dup p.(ala198glyfs*38) 1 Sohocki, GUCA1B 1 c.131g>a p.(arg44his) 1 Fernandez-San Jose, HK1 20 c.2551g>a p.(glu851lys) 1 Sullivan, IMPDH1 8 c.585t>g p.(phe195leu) 1 This study IMPDH1 9 c.809t>g p.(leu270arg) 1 Borras, IMPDH1 10 c.926g>c p.(arg309pro) 2 Kennan, IMPDH1 10 c.931g>a p.(asp311asn) 1 Bowne, IMPDH1 10 c.962c>t p.(ala321val) 1 Fernandez-San Jose, NR2E3 2 c.166g>a p.(gly56arg) 7 Coppieters, NRL 2 c.152c>t p.(pro51leu) 2 Martinez-Gimeno, NRL 2 c.287t>c p.(met96thr) 1 Hernan, PROM1 12 c.1117c>t p.(arg373cys) 1 Yang, PRPF3 11 c.1481c>t p.(thr494met) 3 Chakarova, PRPF31 2 c.55del p.(glu19lysfs*46) 1 This study PRPF31 4 c.322þ4_322þ7del p.(?) 2 Zhang, PRPF31 5 c.328_330del p.(ile110del) 1 de Sousa Dias, PRPF31 IVS6þ1 c.527þ1g>t p.(?) 1 Chakarova, PRPF31 7 c.541g>t p.(glu181*) 2 Pomares, PRPF31 8 c.736g>a p.(ala246thr) 1 Xu, PRPF31 8 c.770dup p.(thr258aspfs*21) 1 Vithana, PRPF31 8 c.828_829del p.(his276glnfs*2) 1 Martinez-Gimeno, PRPF31 9 c.895t>c p.(cys299arg) 1 Sullivan, PRPF31 9 c.939dup p.(gly314argfs*10) 1 Fernandez-San Jose, PRPF31 IVS10 1 c G>T p.(?) 1 Martin-Merida, PRPF31 IVS11þ2 c.1146þ2t>c p.(?) 1 Waseen, PRPF31 IVS11þ2 c.1146þ2t>a p.(?) 1 Martin-Merida, PRPF31 14 c.1462_1472del p.(lys488argfs*75) 1 This study PRPF6 IVS17þ1 c.2339þ1g>a p.(?) 1 This study PRPF8 43 c.6893_6896delinsccataga p.(leu2298_ala2299delinsproileglu) 1 Martinez-Gimeno, PRPF8 43 c.6974_6994del p.(val2325_glu2331del) 1 Martinez-Gimeno, PRPF8 43 c.6928a>g p.(arg2310gly) 1 McKie, PRPH2 1 c.536g>t p.(trp179leu) 1 Kitiratschky, PRPH2 1 c.556g>a p.(asp186asn) 1 Fernandez-San Jose, PRPH2 IVS1 1 c.582 1G>A p.(?) 2 Fernandez-San Jose, PRPH2 2 c.584g>t p.(arg195leu) 1 Yanagihashi, PRPH2 2 c.623g>a p.(gly208asp) 1 Kohl, PRPH2 2 c.634a>g p.(ser212gly) 2 Farrar, PRPH2 2 c.643a>t p.(asn215tyr) 1 This study PRPH2 2 c.646c>t p.(pro216ser) 1 Fishman, RHO 1 c.44a>g p.(asn15ser) 1 Kranich, RHO 1 c.50c>t p.(thr17met) 2 Sheffield, RHO 1 c.84g>c p.(gln28his) 2 Fernandez-San Jose, RHO 1 c.131t>c p.(met44thr) 1 Reig, RHO 1 c.173c>g p.(thr58arg) 2 Dryja, RHO 1 c.180c>a p.(tyr60*) 1 Eisenberger, RHO 1 c.236t>c p.(leu79pro) 1 Fernandez-San Jose, RHO 1 c.290c>t p.(thr97ile) 1 Fernandez-San Jose, RHO 1 c.316g>a p.(gly106arg) 2 Inglehearn, RHO 2 c.378g>a p.(tyr126*) 1 Fernandez-San Jose, RHO 2 c.404g>t p.(arg135leu) 2 Andreasson, RHO 2 c.403c>t p.(arg135trp) 5 Sung, RHO 2 c.491c>a p.(ala164glu) 3 Vaithinathan, RHO 2 c.488t>c p.(met163thr) 1 Fernandez-San Jose, RHO 2 c.500g>a p.(cys167tyr) 2 Fernandez-San Jose, RHO 2 c.509c>g p.(pro170arg) 1 Sohocki, RHO 2 c.512c>t p.(pro171leu) 1 Dryja, RHO IVS2 2 c.531 2A>G p.(?) 1 Martinez-Gimeno, RHO 3 c.533a>g p.(tyr178cys) 1 Sung, RHO 3 c.541g>a p.(glu181lys) 2 Dryja, RHO 3 c.544g>a p.(gly182ser) 3 Sheffield,

5 Comprehensive Genetic Analysis of Spanish adrp Families IOVS j May 2018 j Vol. 59 j No. 6 j 2349 TABLE 2. Continued Gene Exon Nucleotide Change Protein Change No. Families Reference RHO 3 c.545g>t p.(gly182val) 1 Yang, RHO 3 c.556t>c p.(ser186pro) 1 Dryja, RHO 3 c.562g>a p.(gly188arg) 1 Dryja, RHO 3 c.568g>t p.(asp190tyr) 2 al-maghtheh, RHO 3 c.644c>t p.(pro215leu) 1 Martinez-Gimeno, RHO 4 c.865a>c p.(thr289pro) 1 Martinez-Gimeno, RHO 5 c.1040c>t p.(pro347leu) 10 Dryja, RP1 4 c.1981g>t p.(glu661*) 1 Fernandez-San Jose, RP1 4 c.2029c>t p.(arg677*) 1 Pierce, RP1 4 c.2056 C>T p.(gln686*) 1 Gamundi, RP1 4 c.2080g>t p.(gly694*) 1 This study RP1 4 c.2115dela p.(gly706valfs*7) 1 Gamundi, RP1 4 c.2164_2165delinsg p.(lys722glufs*16) 1 This study RP1 4 c.2232t>a p.(cys744*) 1 Bowne, RP1 4 c.2288del p.(asn763ilefs*12) 1 Fernandez-San Jose, RP1 4 c.2289_2299del p.(asn763lysfs*14) 1 This study RP1 4 c.2745_2749del p.(tyr915*) 1 Fernandez-San Jose, RP1 4 c.4328g>a p.(arg1443gln) 1 Fernandez-San Jose, SNRNP c.2041c>t p.(arg681cys) 2 Benaglio, SNRNP c.2042g>a p.(arg681his) 1 Benaglio, SNRNP c.2359g>a p.(ala787thr) 1 Xu, SNRNP c.3260c>t p.(ser1087leu) 2 Zhao, TOPORS 3 c.2518_2519del p.(ser840*) 2 This study TOPORS 3 c.2524dup p.(thr842asnfs*31) 1 This study C1QTNF5 15 c.489c>a p.(ser163arg) 4 Hayward, RPGR 6 c.485_486del p.(phe162tyrfs*4) 1 Sharon, RPGR 8 c.888_889del p.(ile297lysfs*48) 1 This study RPGR 15 c.2405_2406del p.(glu802glyfs*32) 1 Vervoort, RPGR 15 c.2296_2299del p.(gly766asnfs*48) 1 This study CHM 5 c.340g>t p.(glu114*) 1 This study CHM 6 c.757c>t p.(arg253*) 1 Hayakawa, RP2 1 c.1a>g p.(met1?) 1 This study RP2 1 c.14_16del p.(phe5del) 1 Neidhardt, ABCA4 8 c.950del p.(gly317alafs*57) 1 Corton, c.2888del p.(gly963alafs*14) 1 Paloma, c.6688del p.(leu2230serfs*17) 1 This study CNGA1 5 c.94c>t p.(arg32*) 1 Paloma, c.131del p.(glu44glyfs*49) 1 This study EYS IVS28 c A>G p.(?) 1 Gonzalez-del Pozo, RDH5 4 c.625c>t p.(arg209*) 1 Schatz, c.776c>t p.(pro259leu) 1 This study USH2A 13 c.2299del p.(glu767serfs*21) 1 Eudy, c.12094g>a p.(gly4032arg) 1 Ge, In bold: mutations described in our cohort for the first time. ment on fundus examination. As with the genetic findings, these symptoms were compatible with the features of retinitis punctata albescens. The proband with variants in USH2A, did not have hearing loss, and no such symptom was reported in the family history. Therefore, the phenotype was suggestive of RP rather than Usher syndrome. In the family carrying ABCA4 mutations, the phenotype was compatible with a cone-rod dystrophy, with progressive loss of visual acuity followed by visual field constriction and total blindness at 45 years of age. DISCUSSION We present the largest mutational screening carried out in an adrp cohort with European ancestry, specifically constituted of Spanish families. Therefore, our study provides an accurate overview of the prevalence of adrp-associated genes and mutational events. This cohort has been screened for more than 25 years by means of the molecular strategies available at the time, which gives us an interesting insight into how diagnostic rates for adrp have changed over time with the development of more innovative and high-throughput techniques. Direct or indirect screening of the most frequently mutated genes in combination with genotyping microarrays achieved a significant diagnostic rate of 38%. After NGS and CNV analysis, the overall detection rate in our cohort increased to 60%. This is higher than that found in the German (41%) 10 and Belgian cohorts (56%), 17 but lower than the 78.5% reported by the most comprehensive study to date, performed on a large North American cohort. 5 The presence of the founder p.pro23his mutation in RHO, which is almost exclusively from the United States, in 13.2% of American adrp families 5 could explain the difference in detection rates between the two cohorts. Additionally, our cohort had greater

6 Comprehensive Genetic Analysis of Spanish adrp Families IOVS j May 2018 j Vol. 59 j No. 6 j 2350 TABLE 3. Large Genomic Rearrangements on 19q13.42, 19q13.32, and 3q22.1, Affecting PRPF31, CRX, and RHO, Respectively Minimum Size, bp Reference Genomic Coordinates (hg19) Type of Rearrangement Involved Genes Technique Validation Family WES acgh chr19:54,602,946 54,635,178 32,232 Almoguera, RP-0777 Deletion OSCAR (E1 to E2), NDUFA3, TFPT, and entire PRPF31 MLPA acgh chr19:54,602,946 54,632,693 29,747 Martin-Merida, RP-0932 Deletion OSCAR (E1 to E2), NDUFA3, TFPT, and PRPF31 (E1 to E13) RP-0932 Duplication PRPF31 (E2 to E5) MLPA acgh chr19:54,621,606 54,626,745 5,139 Martin-Merida, RP-2426 Deletion PRPF31 (E1) MLPA acgh chr19:54,618,828 54,619, Martin-Merida, RP-0076 Deletion PRPF31 (E9) NGS MLPA chr19:54,629,903 54,629, This study RP-1092 Deletion CRX (E3 to E4) NGS MLPAþaCGH chr19:48,339,216 48,345,529 6,313 Bravo-Gil, RP-1192 Deletion CRX (E3 to E4) NGS MLPAþaCGH chr19: 48,339,345 48,347,355 8,010 Bravo-Gil, RP-1383 Deletion RHO (E5) MLPA Sanger chr3:129,251, ,252, De Sousa Dias, In bold: mutations described in our cohort for the first time. TABLE 4. Prevalence of Disease-Causing Mutation in 258 adrp Spanish Families, Including Types of Mutation in Each Gene Gene No. Families % MS FS NS SP CNV Other ad gene RHO PRPF RP PRPH NR2E SNRNP IMPDH CRX NRL PRPF PRPF TOPORS BEST GUCA1B HK PROM PRPF adrd gene C1QTNF Other inheritance patterns RPGR CHM RP ABCA CNGA EYS RDH USH2A Not solved Total ad, autosomal dominant; FS, frameshift; MS, missense; NS, nonsense; Other, start loss, and in-frame variants; SP, splicing. allelic diversity. Our study is also somewhat biased, as 34 (13.2%) of our 258 adrp families could not be studied by NGS; therefore, it is likely that the rate of characterized families has been slightly underestimated. Taking into account that 66% of naïve cases were characterized when NGS was applied as a first-tier approach, the actual diagnostic yield for adrp is expected to be between 60% and 70%. In our cohort, mutations in RHO and PRPF31 were the most prevalent, explaining 21% and 8% of our families, respectively, followed by RP1 and PRPH2. Supplementary Table S3 shows the characterization rate and the percentage of mutations in these genes in different adrp populations. The frequency of involvement of the adrp-associated genes is quite similar to that reported for adrp in the US population, 5 with the exception of RP1, which is the fifth most prevalent mutated gene after PRPH2 and RPGR. 5 RHO is known to be the most prevalent adrp-associated gene worldwide; however, the prevalence and mutational spectrum of this gene seem to vary according to the population studied, ranging from 7% in South Africa 18 to 31% in American cohorts. 5 Most of the variants (89 variants) identified in our population were private mutations for their respective family, 18 mutations were seen twice, and 7 different mutations in the RHO, NR2E3, C1QTNF5, and PRPF3 genes were found in three or more families, accounting for 13.6% of the solved families. Among them, the most prevalent mutations seen in our cohort were the p.(pro347leu) in the RHO gene, described as a

7 Comprehensive Genetic Analysis of Spanish adrp Families IOVS j May 2018 j Vol. 59 j No. 6 j 2351 FIGURE. Overview of novel CNVs identified in this study. (A) Schematic representation of deletions in the CRX and PRPF31 genes in three patients by read-depth NGS data analysis. Each exon is represented by a circle. Normal exons are indicated in black and deleted exons are indicated in red. (B) Refinement by acgh analysis of CRX deletions on chromosome 19 in families RP-1192 and RP Red bar represents the genomic positions of the minimum and maximum deletion size of 8010 bp (chr19: ) and bp (chr19: ), respectively, in family RP Green bar represents the genomic positions of the minimum and maximum deletion size of 6313 bp (chr19: ) and bp (chr19: ), respectively, in family RP The intragenic marker D19S902 is represented by a black rectangle. Schematic representation of the complete intron-exon structure of CRX in blue and the repeat element (SINE) in black are shown. Exons are indicated by rectangles. (C) Validation of the deletion in the PRPF31 gene by MLPA and segregation analysis in the RP-0076 family. The segregation analysis showed incomplete penetrance, as individual III:3 was an asymptomatic carrier. hotspot, 11 followed by the founder mutation p.(gly56arg) in the NR2E3 gene in our population. 19 For the other five variants p.(arg135trp), p.(ala164glu), and p.(gly182ser) in RHO, p.(ser163arg) in C1QTNF5, and p.(thr494met) in the PRPF3 gene, it would be necessary to perform haplotype analyses in these families to determinate if these variants are founder mutations in our population. Recently, pathogenic CNVs have been found to be an important and underestimated cause of human retinal dystrophies. 13 Multi-exon deletions have been described in several IRD-associated genes, accounting for an increasing percentage of uncharacterized patients. 13 Our study was pioneering in the implementation of comprehensive CNV analysis for molecular characterization of adrp, using both MLPA and/or read-depth NGS analysis, highlighting the important role of structural variants in the etiology of adrp. Remarkably, up to 3.1% of our patients carried this type of underestimated variant, mainly in PRPF31 and CRX. The high frequency of CNVs for both genes could be related to their genomic location on chromosome 19, which is a well-known enriched region in Alu repeats. 20 Similar to that described for genomic PRPF31 rearrangements, 21 the most plausible mechanism underlying gross CRX deletions seems to be a nonallelic homologous recombination between nearly identical Alu repeats, which are present at both 5 0 and 3 0 boundaries of the deleted regions (Fig.). Interestingly, the proportion of structural variants in both genes was similar to that obtained for truncated variants. However, with the exception of the CRX, PRPF31, RP1, and TOPORS genes, missense variants were the most prevalent cause of adrp in our cohort, presumably due to a mechanism different from haploinsufficiency. Thus, the adrp-associated disease mechanism seems to be gene-specific, but also it may also be related to the type of defect and gene localization. We carried out a hypothesis-free analysis using different targeted NGS approaches that include genes not only associated with RP but also with other rare forms of IRD, which allowed us to perform clinical and genetic reclassification of some families. In four families, we found the pathogenic variant p.(ser163arg) in the C1QTNF5 gene that has been previously associated with a characteristic phenotype of lateonset retinal degeneration (LORD). 16,22 This retinal form is an autosomal dominant ocular disease characterized mainly by night blindness in the fifth and sixth decades of life, in which patients showed mottled yellow-white deposits, central and peripheral degeneration, and choroidal neovascularization on eye fundus. 22 Index cases from these four families noticed night blindness as the first symptom at 50 to 60 years and were referred to our center with an initial diagnosis of late-onset RP, some of them presented with macular alterations and drusoid material on fundus examination. LORD can be easily misdiagnosed as AMD or classical RP in early or later stages of disease, respectively. 16 In view of the relative high frequency of this variant in our cohort and the inherent difficulty of LORD clinical diagnosis, we believe that this gene should be taken into consideration during NGS screening of cases with suspected clinical diagnosis of late-onset RP.

8 Comprehensive Genetic Analysis of Spanish adrp Families IOVS j May 2018 j Vol. 59 j No. 6 j 2352 Eight families carrying pathogenic variants on X-linked genes were initially misclassified as adrp due the presence of affected females. Mutations in the X-linked RP genes, RPGR and RP2, have been previously described in up to 8.5% of families with initial diagnosis of adrp and affected carrier females. 23 It is well known that there is a large proportion of causal mutations at the 3 0 end of RPGR, a highly repetitive region of exon open reading frame 15 (ORF15), that is poorly covered in the NGS assays. 22 Our proportion of characterized adrp families with diseasecausing mutation in RPGR and RP2 is lower (2.4%) than reported by Churchill et al., 23 and it could be because some mutations in this region could be missed by capture-based NGS approaches. This highlights the need of ORF15 screening by alternative Sanger sequencing in all uncharacterized adrp families with no male-to-male transmission. Although carrier females of CHM mutations are usually asymptomatic, 24 there are some previously reported cases of females fully affected by choroideremia. 25 This complete penetrance of heterozygous CHM variants could be explained by nonrandom lyonization of chromosome X, inactivating the wild-type allele. 26 Choroideremia is generally a clinical diagnosis made by eye-fundus examination and family history, 27 although in our two families the available phenotypic and pedigree data were scarce, and therefore the diagnosis mainly relied on the results of molecular genetic testing. Therefore, it would be highly recommended to perform an ophthalmologic examination in these families. In five additional cases, unexpected biallelic pathogenic variants for known recessive genes were identified. In the RP family, the observed pseudo-dominant pattern was explained by the segregation of a homozygous variant in several consecutive generations in a context of high inbreeding. Additionally, pseudo-dominant inheritance in other families may also be justified by the relatively high carrier frequency of some mutations in the Spanish population for some IRD genes with high allelic heterogeneity. 28 This is the case of family RP-1455, with three different pathogenic ABCA4 variants segregating over several generations. There are several reasons that would explain the lack of causative variants in the noncharacterized studied patients. First, some families could carry disease-causing variants in regions not targeted by our NGS approaches, such as deep intronic regions of the studied genes, recently identified adrpassociated genes (ADIPOR1, ARL3, PRPF4, and SPP2), or novel genes not yet discovered. Second, despite the successful identification of genomic rearrangements in this study, we could not rule out the possibility that there may be additional CNVs involving partially covered regions by the NGS approaches used here. Therefore, further WES and/or wholegenome sequencing studies in these uncharacterized patients could help us to identify novel adrp genes. In conclusion, the combination of different strategies in adrp molecular testing over time has allowed us to achieve high diagnostic rates in our Spanish cohort. Our study confirms the great diagnostic value of gene panel based NGS tools, which currently represent the most reliable, cost-effective, and efficient approaches for identifying not only disease-causing SNVs, but also CNVs in adrp families. It was also evidenced that the use of a hypothesis-free approach allows for the genetic and/or phenotypic reclassification of a relevant number of families, which could have a huge impact on family counseling, clinical follow-up, and future enrollment in gene therapy based treatments. Acknowledgments The authors thank the Genetics and Ophthalmology Departments of the Fundación Jiménez Díaz University Hospital (Madrid, Spain), Oliver Shaw for English review and editing the manuscript, and all patients and doctors who participated in the study. Supported by grants from the Instituto de Salud Carlos III (ISCIII) of the Spanish Ministry of Health, including CIBERER (06/07/ 0036), FIS FEDER (European Regional Development Fund) (PI16/ 00425), and IIS-FJD Biobank PT13/0010/0012. In addition, the Spanish National Organization for the Blind (ONCE), the Spanish Fighting Blindness Foundation (FUNDALUCE), and the Ramon Areces Foundation also supported this work. IM-M is sponsored by the IIS-Fundación Jiménez Díaz-UAM Genomic Medicine Chair. MC is supported by the Miguel Servet Program (CP12/03256) from ISCIII. Disclosure: I. Martin-Merida, None; D. Aguilera-Garcia, None; P. Fernandez-San Jose, None; F. Blanco-Kelly, None; O. Zurita, None; B. Almoguera, None; B. Garcia-Sandoval, None; A. Avila-Fernandez, None; A. Arteche, None; P. Minguez, None; M. Carballo, None; M. Corton, None; C. Ayuso, None References 1. Hamel C. Retinitis pigmentosa. Orphanet J Rare Dis. 2006;1: Berger W, Kloeckener-Gruissem B, Neidhardt J. The molecular basis of human retinal and vitreoretinal diseases. Prog Retin Eye Res. 2010;29: Ayuso C, Millan JM. Retinitis pigmentosa and allied conditions today: a paradigm of translational research. Genome Med. 2010;2: Ayuso C, Garcia-Sandoval B, Najera C, Valverde D, Carballo M, Antinolo G; The Spanish Multicentric and Multidisciplinary Group for Research into Retinitis Pigmentosa. Retinitis pigmentosa in Spain. Clin Genet. 1995;48: Daiger SP, Bowne SJ, Sullivan LS. Genes and mutations causing autosomal dominant retinitis pigmentosa. Cold Spring Harb Perspect Med. 2014;5:a Martinez-Gimeno M, Gamundi MJ, Hernan I, et al. Mutations in the pre-mrna splicing-factor genes PRPF3, PRPF8, and PRPF31 in Spanish families with autosomal dominant retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2003;44: Blanco-Kelly F, Garcia-Hoyos M, Corton M, et al. Genotyping microarray: mutation screening in Spanish families with autosomal dominant retinitis pigmentosa. Mol Vis. 2012;18: Fernandez-San Jose P, Corton M, Blanco-Kelly F, et al. Targeted next-generation sequencing improves the diagnosis of autosomal dominant retinitis pigmentosa in Spanish patients. Invest Ophthalmol Vis Sci. 2015;56: Bravo-Gil N, Mendez-Vidal C, Romero-Perez L, et al. Improving the management of inherited retinal dystrophies by targeted sequencing of a population-specific gene panel. Sci Rep. 2016; 6: Glockle N, Kohl S, Mohr J, et al. Panel-based next generation sequencing as a reliable and efficient technique to detect mutations in unselected patients with retinal dystrophies. Eur J Hum Genet. 2014;22: Oishi M, Oishi A, Gotoh N, et al. Comprehensive molecular diagnosis of a large cohort of Japanese retinitis pigmentosa and Usher syndrome patients by next-generation sequencing. Invest Ophthalmol Vis Sci. 2014;55: Martin-Merida I, Sanchez-Alcudia R, Fernandez-San Jose P, et al. Analysis of the PRPF31 gene in Spanish autosomal dominant retinitis pigmentosa patients: a novel genomic rearrangement. Invest Ophthalmol Vis Sci. 2017;58: Ellingford JM, Horn B, Campbell C, et al. Assessment of the incorporation of CNV surveillance into gene panel nextgeneration sequencing testing for inherited retinal diseases. J Med Genet. 2018;55:

9 Comprehensive Genetic Analysis of Spanish adrp Families IOVS j May 2018 j Vol. 59 j No. 6 j Fernandez-San Jose P, Blanco-Kelly F, Corton M, et al. Prevalence of rhodopsin mutations in autosomal dominant retinitis pigmentosa in Spain: clinical and analytical review in. 200 families. Acta Ophthalmol. 2015;93:e38 e de Sousa Dias M, Hernan I, Pascual B, et al. Detection of novel mutations that cause autosomal dominant retinitis pigmentosa in candidate genes by long-range PCR amplification and next-generation sequencing. Mol Vis. 2013;19: Almoguera B, Li J, Fernandez-San Jose P, et al. Application of whole exome sequencing in six families with an initial diagnosis of autosomal dominant retinitis pigmentosa: lessons learned. PLoS One. 2015;10:e Van Cauwenbergh C, Coppieters F, Roels D, et al. Mutations in splicing factor genes are a major cause of autosomal dominant retinitis pigmentosa in Belgian families. PLoS One. 2017;12: e Roberts L, Ramesar R, Greenberg J. Low frequency of rhodopsin mutations in South African patients with autosomal dominant retinitis pigmentosa. Clin Genet. 2000;58: Blanco-Kelly F, Garcia Hoyos M, Lopez Martinez MA, et al. Dominant retinitis pigmentosa, p.gly56arg nutation in NR2E3: phenotype in a large cohort of 24 cases. PLoS One. 2016;11:e Grover D, Mukerji M, Bhatnagar P, Kannan K, Brahmachari SK. Alu repeat analysis in the complete human genome: trends and variations with respect to genomic composition. Bioinformatics. 2004;20: Rose AM, Mukhopadhyay R, Webster AR, Bhattacharya SS, Waseem NH. A 112 kb deletion in chromosome 19q13.42 leads to retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2011;52: Hayward C, Shu X, Cideciyan AV, et al. Mutation in a shortchain collagen gene, CTRP5, results in extracellular deposit formation in late-onset retinal degeneration: a genetic model for age-related macular degeneration. Hum Mol Genet. 2003; 12: Churchill JD, Bowne SJ, Sullivan LS, et al. Mutations in the X- linked retinitis pigmentosa genes RPGR and RP2 found in 8.5% of families with a provisional diagnosis of autosomal dominant retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2013;54: Ma KK, Lin J, Boudreault K, Chen RW, Tsang SH. Phenotyping choroideremia and its carrier state with multimodal imaging techniques. Retin Cases Brief Rep. 2017;11(Suppl 1):S178 S Fraser GR, Friedmann AI. Choroideremia in a female. Br Med J. 1968;2: Perez-Cano HJ, Garnica-Hayashi RE, Zenteno JC. CHM gene molecular analysis and X-chromosome inactivation pattern determination in two families with choroideremia. Am J Med Genet A. 2009;149A: MacDonald IM, Hume S, Chan S, Seabra MC. Choroideremia. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. Gene- Reviewst. Seattle, WA: University of Washington, Seattle; Riveiro-Alvarez R, Aguirre-Lamban J, Lopez-Martinez MA, et al. Frequency of ABCA4 mutations in 278 Spanish controls: an insight into the prevalence of autosomal recessive Stargardt disease. Br J Ophthalmol. 2009;93: Davidson AE, Millar ID, Urquhart JE, et al. Missense mutations in a retinal pigment epithelium protein, bestrophin-1, cause retinitis pigmentosa. Am J Hum Genet. 2009;85: Swain PK, Chen S, Wang QL, et al. Mutations in the cone-rod homeobox gene are associated with the cone-rod dystrophy photoreceptor degeneration. Neuron. 1997;19: Sohocki MM, Sullivan LS, Mintz-Hittner HA, et al. A range of clinical phenotypes associated with mutations in CRX, a photoreceptor transcription-factor gene. Am J Hum Genet. 1998;63: Sullivan LS, Koboldt DC, Bowne SJ, et al. A dominant mutation in hexokinase 1 (HK1) causes retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2014;55: Borras E, de Sousa Dias M, Hernan I, et al. Detection of novel genetic variation in autosomal dominant retinitis pigmentosa. Clin Genet. 2013;84: Kennan A, Aherne A, Palfi A, et al. Identification of an IMPDH1 mutation in autosomal dominant retinitis pigmentosa (RP10) revealed following comparative microarray analysis of transcripts derived from retinas of wild-type and Rho(-/-) mice. Hum Mol Genet. 2002;11: Bowne SJ, Sullivan LS, Blanton SH, et al. Mutations in the inosine monophosphate dehydrogenase 1 gene (IMPDH1) cause the RP10 form of autosomal dominant retinitis pigmentosa. Hum Mol Genet. 2002;11: Coppieters F, Leroy BP, Beysen D, et al. Recurrent mutation in the first zinc finger of the orphan nuclear receptor NR2E3 causes autosomal dominant retinitis pigmentosa. Am J Hum Genet. 2007;81: Martinez-Gimeno M, Maseras M, Baiget M, et al. Mutations P51U and G122E in retinal transcription factor NRL associated with autosomal dominant and sporadic retinitis pigmentosa. Hum Mutat. 2001;17: Hernan I, Gamundi MJ, Borras E, et al. Novel p.m96t variant of NRL and shrna-based suppression and replacement of NRL mutants associated with autosomal dominant retinitis pigmentosa. Clin Genet. 2012;82: Yang Z, Chen Y, Lillo C, et al. Mutant prominin 1 found in patients with macular degeneration disrupts photoreceptor disk morphogenesis in mice. J Clin Invest. 2008;118: Chakarova CF, Hims MM, Bolz H, et al. Mutations in HPRP3, a third member of pre-mrna splicing factor genes, implicated in autosomal dominant retinitis pigmentosa. Hum Mol Genet. 2002;11: Zhang Q, Xu M, Verriotto JD, et al. Next-generation sequencing-based molecular diagnosis of 35 Hispanic retinitis pigmentosa probands. Sci Rep. 2016;6: Chakarova CF, Cherninkova S, Tournev I, et al. Molecular genetics of retinitis pigmentosa in two Romani (Gypsy) families. Mol Vis. 2006;12: Pomares E, Riera M, Permanyer J, et al. Comprehensive SNPchip for retinitis pigmentosa-leber congenital amaurosis diagnosis: new mutations and detection of mutational founder effects. Eur J Hum Genet. 2010;18: Xu Y, Guan L, Shen T, et al. Mutations of 60 known causative genes in 157 families with retinitis pigmentosa based on exome sequencing. Hum Genet. 2014;133: Vithana EN, Abu-Safieh L, Allen MJ, et al. A human homolog of yeast pre-mrna splicing gene, PRP31, underlies autosomal dominant retinitis pigmentosa on chromosome 19q13.4 (RP11). Mol Cell. 2001;8: Sullivan LS, Bowne SJ, Birch DG, et al. Prevalence of diseasecausing mutations in families with autosomal dominant retinitis pigmentosa: a screen of known genes in 200 families. Invest Ophthalmol Vis Sci. 2006;47: Waseem NH, Vaclavik V, Webster A, Jenkins SA, Bird AC, Bhattacharya SS. Mutations in the gene coding for the premrna splicing factor, PRPF31, in patients with autosomal dominant retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2007;48: McKie AB, McHale JC, Keen TJ, et al. Mutations in the premrna splicing factor gene PRPC8 in autosomal dominant retinitis pigmentosa (RP13). Hum Mol Genet. 2001;10:

10 Comprehensive Genetic Analysis of Spanish adrp Families IOVS j May 2018 j Vol. 59 j No. 6 j Kitiratschky VB, Glockner CJ, Kohl S. Mutation screening of the GUCA1B gene in patients with autosomal dominant cone and cone rod dystrophy. Ophthalmic Genet. 2011;32: Yanagihashi S, Nakazawa M, Kurotaki J, Sato M, Miyagawa Y, Ohguro H. Autosomal dominant central areolar choroidal dystrophy and a novel Arg195Leu mutation in the peripherin/ RDS gene. Arch Ophthalmol. 2003;121: Kohl S, Christ-Adler M, Apfelstedt-Sylla E, et al. RDS/ peripherin gene mutations are frequent causes of central retinal dystrophies. J Med Genet. 1997;34: Farrar GJ, Kenna P, Jordan SA, et al. Autosomal dominant retinitis pigmentosa: a novel mutation at the peripherin/rds locus in the original 6p-linked pedigree. Genomics. 1992;14: Fishman GA, Stone E, Gilbert LD, Vandenburgh K, Sheffield VC, Heckenlively JR. Clinical features of a previously undescribed codon 216 (proline to serine) mutation in the peripherin/retinal degeneration slow gene in autosomal dominant retinitis pigmentosa. Ophthalmology. 1994;101: Kranich H, Bartkowski S, Denton MJ, et al. Autosomal dominant sector retinitis pigmentosa due to a point mutation predicting an Asn-15-Ser substitution of rhodopsin. Hum Mol Genet. 1993;2: Sheffield VC, Fishman GA, Beck JS, Kimura AE, Stone EM. Identification of novel rhodopsin mutations associated with retinitis pigmentosa by GC-clamped denaturing gradient gel electrophoresis. Am J Hum Genet. 1991;49: Reig C, Antich J, Gean E, et al. Identification of a novel rhodopsin mutation (Met-44-Thr) in a simplex case of retinitis pigmentosa. Hum Genet. 1994;94: Dryja TP, McGee TL, Hahn LB, et al. Mutations within the rhodopsin gene in patients with autosomal dominant retinitis pigmentosa. N Engl J Med. 1990;323: Eisenberger T, Neuhaus C, Khan AO, et al. Increasing the yield in targeted next-generation sequencing by implicating CNV analysis, non-coding exons and the overall variant load: the example of retinal dystrophies. PLoS One. 2013;8:e Inglehearn CF, Keen TJ, Bashir R, et al. A completed screen for mutations of the rhodopsin gene in a panel of patients with autosomal dominant retinitis pigmentosa. Hum Mol Genet. 1992;1: Andreasson S, Ehinger B, Abrahamson M, Fex G. A sixgeneration family with autosomal dominant retinitis pigmentosa and a rhodopsin gene mutation (arginine-135-leucine). Ophthalmic Paediatr Genet. 1992;13: Sung CH, Davenport CM, Hennessey JC, et al. Rhodopsin mutations in autosomal dominant retinitis pigmentosa. Proc Natl Acad Sci U S A. 1991;88: Vaithinathan R, Berson EL, Dryja TP. Further screening of the rhodopsin gene in patients with autosomal dominant retinitis pigmentosa. Genomics. 1994;21: Sohocki MM, Daiger SP, Bowne SJ, et al. Prevalence of mutations causing retinitis pigmentosa and other inherited retinopathies. Hum Mutat. 2001;17: Dryja TP, Hahn LB, Cowley GS, McGee TL, Berson EL. Mutation spectrum of the rhodopsin gene among patients with autosomal dominant retinitis pigmentosa. Proc Natl Acad Sci U S A. 1991;88: Martinez-Gimeno M, Trujillo MJ, Lorda I, et al. Three novel mutations (P215L, T289P, and A >G) in the rhodopsin gene in autosomal dominant retinitis pigmentosa in Spanish families. Hum Mutat. 2000;16: Yang G, Xie S, Feng N, Yuan Z, Zhang M, Zhao J. Spectrum of rhodopsin gene mutations in Chinese patients with retinitis pigmentosa. Mol Vis. 2014;20: al-maghtheh M, Gregory C, Inglehearn C, Hardcastle A, Bhattacharya S. Rhodopsin mutations in autosomal dominant retinitis pigmentosa. Hum Mutat. 1993;2: Pierce EA, Quinn T, Meehan T, McGee TL, Berson EL, Dryja TP. Mutations in a gene encoding a new oxygen-regulated photoreceptor protein cause dominant retinitis pigmentosa. Nat Genet. 1999;22: Gamundi MJ, Hernan I, Martinez-Gimeno M, et al. Three novel and the common Arg677Ter RP1 protein truncating mutations causing autosomal dominant retinitis pigmentosa in a Spanish population. BMC Med Genet. 2006;7: Bowne SJ, Daiger SP, Hims MM, et al. Mutations in the RP1 gene causing autosomal dominant retinitis pigmentosa. Hum Mol Genet. 1999;8: Benaglio P, McGee TL, Capelli LP, Harper S, Berson EL, Rivolta C. Next generation sequencing of pooled samples reveals new SNRNP200 mutations associated with retinitis pigmentosa. Hum Mutat. 2011;32:E2246 E Zhao C, Bellur DL, Lu S, et al. Autosomal-dominant retinitis pigmentosa caused by a mutation in SNRNP200, a gene required for unwinding of U4/U6 snrnas. Am J Hum Genet. 2009;85: Sharon D, Bruns GA, McGee TL, Sandberg MA, Berson EL, Dryja TP. X-linked retinitis pigmentosa: mutation spectrum of the RPGR and RP2 genes and correlation with visual function. Invest Ophthalmol Vis Sci. 2000;41: Vervoort R, Lennon A, Bird AC, et al. Mutational hot spot within a new RPGR exon in X-linked retinitis pigmentosa. Nat Genet. 2000;25: Hayakawa M, Fujiki K, Hotta Y, et al. Visual impairment and REP-1 gene mutations in Japanese choroideremia patients. Ophthalmic Genet. 1999;20: Neidhardt J, Glaus E, Lorenz B, et al. Identification of novel mutations in X-linked retinitis pigmentosa families and implications for diagnostic testing. Mol Vis. 2008;14: Corton M, Nishiguchi KM, Avila-Fernandez A, et al. Exome sequencing of index patients with retinal dystrophies as a tool for molecular diagnosis. PLoS One. 2013;8:e Paloma E, Martinez-Mir A, Vilageliu L, Gonzalez-Duarte R, Balcells S. Spectrum of ABCA4 (ABCR) gene mutations in Spanish patients with autosomal recessive macular dystrophies. Hum Mutat. 2001;17: Paloma E, Martinez-Mir A, Garcia-Sandoval B, et al. Novel homozygous mutation in the alpha subunit of the rod cgmp gated channel (CNGA1) in two Spanish sibs affected with autosomal recessive retinitis pigmentosa. J Med Genet. 2002; 39:E Gonzalez-del Pozo M, Borrego S, Barragan I, et al. Mutation screening of multiple genes in Spanish patients with autosomal recessive retinitis pigmentosa by targeted resequencing. PLoS One. 2011;6:e Schatz P, Preising M, Lorenz B, et al. Lack of autofluorescence in fundus albipunctatus associated with mutations in RDH5. Retina. 2010;30: Eudy JD, Weston MD, Yao S, et al. Mutation of a gene encoding a protein with extracellular matrix motifs in Usher syndrome type IIa. Science. 1998;280: Ge Z, Bowles K, Goetz K, et al. NGS-based molecular diagnosis of 105 eyegene((r)) probands with retinitis pigmentosa. Sci Rep. 2015;5: de Sousa Dias M, Hernan I, Delas B, et al. New COL6A6 variant detected by whole-exome sequencing is linked to break points in intron 4 and 3 0 -UTR, deleting exon 5 of RHO, and causing adrp. Mol Vis. 2015;21:

Unravelling the genetic basis of simplex Retinitis Pigmentosa cases

Unravelling the genetic basis of simplex Retinitis Pigmentosa cases SUPPLEMENTARY INFORMATION Unravelling the genetic basis simplex Retinitis Pigmentosa cases Nereida Bravo-Gil 1,2#, María González-del Pozo 1,2#, Marta Martín-Sánchez 1, Cristina Méndez-Vidal 1,2, Enrique

More information

Supplementary appendix

Supplementary appendix Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Ellingford JM, Sergouniotis PI, Lennon R, et

More information

Phenotype Report. Num. Positions Not Called (Missing data) Num. Variants Assessed

Phenotype Report. Num. Positions Not Called (Missing data) Num. Variants Assessed Report Date: August 19, 2015 Software Annotation Version: 8 Report Name: NA12144 NW European Genome : NA12144_S1 Sequencing Provider: Illumina Sequencing Type: Exome : Retinitis Pigmentosa Description:

More information

UKGTN Testing Criteria

UKGTN Testing Criteria UKGTN Testing Criteria Approved name and symbol of disease/condition(s): Retinal Degeneration panel test Approved name and symbol of gene(s): a panel of 105 genes, variants of which have been shown to

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Choroideremia OMIM number for disease 303100 Disease alternative names please

More information

Rhodopsin Gene Codon 106 Mutation (Gly-to-Arg) in a Japanese Family with Autosomal Dominant Retinitis Pigmentosa

Rhodopsin Gene Codon 106 Mutation (Gly-to-Arg) in a Japanese Family with Autosomal Dominant Retinitis Pigmentosa Rhodopsin Gene Codon 106 Mutation (Gly-to-Arg) in a Japanese Family with Autosomal Dominant Retinitis Pigmentosa Budu,* Masayuki Matsumoto, Seiji Hayasaka, Tetsuya Yamada and Yoriko Hayasaka Department

More information

Retinitis pigmentosa (RP) is a group of hereditary retinal

Retinitis pigmentosa (RP) is a group of hereditary retinal Mutations in the Pre-mRNA Splicing-Factor Genes PRPF3, PRPF8, and PRPF31 in Spanish Families with Autosomal Dominant Retinitis Pigmentosa María Martínez-Gimeno, 1,2 María José Gamundi, 1,2 Imma Hernan,

More information

Names for ABO (ISBT 001) Blood Group Alleles

Names for ABO (ISBT 001) Blood Group Alleles Names for ABO (ISBT 001) blood group alleles v1.1 1102 Names for ABO (ISBT 001) Blood Group Alleles General description: The ABO system was discovered as in 1900 and is considered the first and clinically

More information

Molecular Diagnostic Testing by eyegene: Analysis of Patients With Hereditary Retinal Dystrophy Phenotypes Involving Central Vision Loss

Molecular Diagnostic Testing by eyegene: Analysis of Patients With Hereditary Retinal Dystrophy Phenotypes Involving Central Vision Loss Genetics Molecular Diagnostic Testing by eyegene: Analysis of Patients With Hereditary Retinal Dystrophy Phenotypes Involving Central Vision Loss Akhila Alapati, 1 Kerry Goetz, 2 John Suk, 1 Mili Navani,

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Leber congenital amaurosis OMIM number for disease 204000 Disease alternative

More information

Variant association and prioritization

Variant association and prioritization Variant association and prioritization Edinburgh Genomics Marta Bleda Latorre Edinburgh, UK mb2033@cam.ac.uk 23rd October 2015 Research Assistant at the Department of Medicine University of Cambridge Cambridge,

More information

The current status of molecular diagnosis of inherited retinal dystrophies

The current status of molecular diagnosis of inherited retinal dystrophies REVIEW C URRENT OPINION The current status of molecular diagnosis of inherited retinal dystrophies John (Pei-wen) Chiang a and Karmen Trzupek b Purpose of review We are witnessing lightning-fast advances

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Ku CA, Hull S, Arno G, et al. Detailed clinical phenotype and molecular genetic findings in CLN3-associated isolated retinal degeneration. JAMA Ophthalmol. Published online

More information

CURRENT GENETIC TESTING TOOLS IN NEONATAL MEDICINE. Dr. Bahar Naghavi

CURRENT GENETIC TESTING TOOLS IN NEONATAL MEDICINE. Dr. Bahar Naghavi 2 CURRENT GENETIC TESTING TOOLS IN NEONATAL MEDICINE Dr. Bahar Naghavi Assistant professor of Basic Science Department, Shahid Beheshti University of Medical Sciences, Tehran,Iran 3 Introduction Over 4000

More information

RNA-Seq guided gene therapy for vision loss. Michael H. Farkas

RNA-Seq guided gene therapy for vision loss. Michael H. Farkas RNA-Seq guided gene therapy for vision loss Michael H. Farkas The retina is a complex tissue Many cell types Neural retina vs. RPE Each highly dependent on the other Graw, Nature Reviews Genetics, 2003

More information

MEDICAL GENOMICS LABORATORY. Next-Gen Sequencing and Deletion/Duplication Analysis of NF1 Only (NF1-NG)

MEDICAL GENOMICS LABORATORY. Next-Gen Sequencing and Deletion/Duplication Analysis of NF1 Only (NF1-NG) Next-Gen Sequencing and Deletion/Duplication Analysis of NF1 Only (NF1-NG) Ordering Information Acceptable specimen types: Fresh blood sample (3-6 ml EDTA; no time limitations associated with receipt)

More information

INDEX. Genetics. French poodle progressive rod-cone degeneration,

INDEX. Genetics. French poodle progressive rod-cone degeneration, INDEX Acuity in Stargardt's macular dystrophy, 25-34 ADRP (Autosomal dominant retinitis pigmentosa), see Retinitis pigmentosa and Genetics afgf, 294, 296 Age-related maculopathy, see Macular degeneration

More information

Variant prioritization

Variant prioritization Variant prioritization University of Cambridge Marta Bleda Latorre Cambridge, UK mb2033@cam.ac.uk 30th September 2014 Research Assistant at the Department of Medicine University of Cambridge Cambridge,

More information

Names for H (ISBT 018) Blood Group Alleles

Names for H (ISBT 018) Blood Group Alleles Names for H (ISBT 018) Blood Group Alleles General description: The H blood group system consists of one antigen, H, that is carried on glycolipids and glycoproteins on the RBC membrane, where it is synthesised

More information

OPHTHALMIC MOLECULAR GENETICS. SECTION EDITOR: JANEY L. WIGGS, MD, PhD

OPHTHALMIC MOLECULAR GENETICS. SECTION EDITOR: JANEY L. WIGGS, MD, PhD OPHTHALMIC MOLECULAR GENETICS SECTION EDITOR: JANEY L. WIGGS, MD, PhD Association of a Novel Mutation in the Retinol Dehydrogenase 12 (RDH12) Gene With Autosomal Dominant Retinitis Pigmentosa John H. Fingert,

More information

Assessing the phenotypic effects in the general population of rare variants in genes for a dominant Mendelian form of diabetes

Assessing the phenotypic effects in the general population of rare variants in genes for a dominant Mendelian form of diabetes Assessing the phenotypic effects in the general population of rare variants in genes for a dominant Mendelian form of diabetes Supplementary Information Jason Flannick*, Nicola L Beer*, Alexander G Bick,

More information

Identifying Mutations Responsible for Rare Disorders Using New Technologies

Identifying Mutations Responsible for Rare Disorders Using New Technologies Identifying Mutations Responsible for Rare Disorders Using New Technologies Jacek Majewski, Department of Human Genetics, McGill University, Montreal, QC Canada Mendelian Diseases Clear mode of inheritance

More information

Genomic structural variation

Genomic structural variation Genomic structural variation Mario Cáceres The new genomic variation DNA sequence differs across individuals much more than researchers had suspected through structural changes A huge amount of structural

More information

MRC-Holland MLPA. Description version 18; 09 September 2015

MRC-Holland MLPA. Description version 18; 09 September 2015 SALSA MLPA probemix P090-A4 BRCA2 Lot A4-0715, A4-0714, A4-0314, A4-0813, A4-0712: Compared to lot A3-0710, the 88 and 96 nt control fragments have been replaced (QDX2). This product is identical to the

More information

Benefits and pitfalls of new genetic tests

Benefits and pitfalls of new genetic tests Benefits and pitfalls of new genetic tests Amanda Krause Division of Human Genetics, NHLS and University of the Witwatersrand Definition of Genetic Testing the analysis of human DNA, RNA, chromosomes,

More information

Investigating rare diseases with Agilent NGS solutions

Investigating rare diseases with Agilent NGS solutions Investigating rare diseases with Agilent NGS solutions Chitra Kotwaliwale, Ph.D. 1 Rare diseases affect 350 million people worldwide 7,000 rare diseases 80% are genetic 60 million affected in the US, Europe

More information

Screening for mutations in RPGR and RP2 genes in Jordanian families with X-linked retinitis pigmentosa

Screening for mutations in RPGR and RP2 genes in Jordanian families with X-linked retinitis pigmentosa Screening for mutations in RPGR and RP2 genes in Jordanian families with X-linked retinitis pigmentosa M.F. Haddad 1, O.F. Khabour 1, K.A.Y. Abuzaideh 1 and W. Shihadeh 2 1 Faculty of Applied Medical Sciences,

More information

QLT Inc Rationale and Background for the development of QLT (Note: QLT is not approved for commercial use in any countries, worldwide)

QLT Inc Rationale and Background for the development of QLT (Note: QLT is not approved for commercial use in any countries, worldwide) QLT Inc Rationale and Background for the development of QLT091001 (Note: QLT091001 is not approved for commercial use in any countries, worldwide) Introduction QLT Inc. (QLT) is a Canadian company focused

More information

Supplementary Document

Supplementary Document Supplementary Document 1. Supplementary Table legends 2. Supplementary Figure legends 3. Supplementary Tables 4. Supplementary Figures 5. Supplementary References 1. Supplementary Table legends Suppl.

More information

analysis in hereditary breast/ovarian cancer families of Portuguese ancestry

analysis in hereditary breast/ovarian cancer families of Portuguese ancestry Clin Genet 2015: 88: 41 48 Printed in Singapore. All rights reserved Short Report 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd CLINICAL GENETICS doi: 10.1111/cge.12441 The role of targeted

More information

Genetic Defect Underlying Progressive Blindness Uncovered by Strand s Clinical Exome Test

Genetic Defect Underlying Progressive Blindness Uncovered by Strand s Clinical Exome Test CASE STUDY Genetic Defect Underlying Progressive Blindness Uncovered by Strand s Clinical Exome Test Patient Profile Swati Koparkar*, a 33-year-old owner of a handicrafts boutique had been experiencing

More information

THE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF)

THE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF) THE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF) Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA 02210. Vertex and the Vertex triangle logo are registered trademarks of Vertex

More information

Supplementary materials and methods

Supplementary materials and methods Supplementary materials and methods Targeted resequencing RNA probes complementary in sequence to the coding exons (+ 2bp) of target genes were designed using e-array (https://earray.chem.agilent.com/earray/)

More information

JULY 21, Genetics 101: SCN1A. Katie Angione, MS CGC Certified Genetic Counselor CHCO Neurology

JULY 21, Genetics 101: SCN1A. Katie Angione, MS CGC Certified Genetic Counselor CHCO Neurology JULY 21, 2018 Genetics 101: SCN1A Katie Angione, MS CGC Certified Genetic Counselor CHCO Neurology Disclosures: I have no financial interests or relationships to disclose. Objectives 1. Review genetic

More information

Stargardt Disease Caused by a Rare Combination of Double Homozygous Mutations

Stargardt Disease Caused by a Rare Combination of Double Homozygous Mutations 386 CONTINUING MEDICAL EDUCatION :386-91 Stargardt Disease Caused by a Rare Combination of Double Homozygous Mutations Danielius Serapinas, Viltautė Obrikytė, Raimundas Sakalauskas Department of Pulmonology

More information

Merging single gene-level CNV with sequence variant interpretation following the ACMGG/AMP sequence variant guidelines

Merging single gene-level CNV with sequence variant interpretation following the ACMGG/AMP sequence variant guidelines Merging single gene-level CNV with sequence variant interpretation following the ACMGG/AMP sequence variant guidelines Tracy Brandt, Ph.D., FACMG Disclosure I am an employee of GeneDx, Inc., a wholly-owned

More information

Genetic Testing and Analysis. (858) MRN: Specimen: Saliva Received: 07/26/2016 GENETIC ANALYSIS REPORT

Genetic Testing and Analysis. (858) MRN: Specimen: Saliva Received: 07/26/2016 GENETIC ANALYSIS REPORT GBinsight Sample Name: GB4411 Race: Gender: Female Reason for Testing: Type 2 diabetes, early onset MRN: 0123456789 Specimen: Saliva Received: 07/26/2016 Test ID: 113-1487118782-4 Test: Type 2 Diabetes

More information

Supplemental Data: Detailed Characteristics of Patients with MKRN3. Patient 1 was born after an uneventful pregnancy. She presented in our

Supplemental Data: Detailed Characteristics of Patients with MKRN3. Patient 1 was born after an uneventful pregnancy. She presented in our 1 2 Supplemental Data: Detailed Characteristics of Patients with MKRN3 Mutations 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 Patient 1 was born after an uneventful pregnancy. She presented

More information

Low Incidence of Retinitis Pigmentosa Among Heterozygous Carriers of a Specific Rhodopsin Splice Site Mutation

Low Incidence of Retinitis Pigmentosa Among Heterozygous Carriers of a Specific Rhodopsin Splice Site Mutation Low Incidence of Retinitis Pigmentosa Among Heterozygous Carriers of a Specific Rhodopsin Splice Site Mutation Philip J. Rosenfeld, Lauri B. Hahn, Michael A. Sandberg, Thaddeus P. Dryja, and Eliot L. Berson

More information

RPE65-associated Leber Congenital Amaurosis

RPE65-associated Leber Congenital Amaurosis RPE65-associated Leber Congenital Amaurosis Brian Privett, MD, Edwin M. Stone, MD, PhD February 16, 2010 Chief Complaint: Poor fixation at 4 months of age History of Present Illness: This 7 year old female

More information

variant led to a premature stop codon p.k316* which resulted in nonsense-mediated mrna decay. Although the exact function of the C19L1 is still

variant led to a premature stop codon p.k316* which resulted in nonsense-mediated mrna decay. Although the exact function of the C19L1 is still 157 Neurological disorders primarily affect and impair the functioning of the brain and/or neurological system. Structural, electrical or metabolic abnormalities in the brain or neurological system can

More information

Concurrent Practical Session ACMG Classification

Concurrent Practical Session ACMG Classification Variant Effect Prediction Training Course 6-8 November 2017 Prague, Czech Republic Concurrent Practical Session ACMG Classification Andreas Laner / Anna Benet-Pagès 1 Content 1. Background... 3 2. Aim

More information

Molecular scanning of the ABCA4 gene in Spanish patients with retinitis pigmentosa and Stargardt disease: Identification of novel mutations

Molecular scanning of the ABCA4 gene in Spanish patients with retinitis pigmentosa and Stargardt disease: Identification of novel mutations European Journal of Ophthalmology / Vol. 17 no. 5, 2007 / pp. 749-754 Molecular scanning of the ABCA4 gene in Spanish patients with retinitis pigmentosa and Stargardt disease: Identification of novel mutations

More information

Analysis of Peripherin/RDS Gene for Japanese Retinal Dystrophies

Analysis of Peripherin/RDS Gene for Japanese Retinal Dystrophies Analysis of Peripherin/RDS Gene for Japanese Retinal Dystrophies Keiko Fujiki,* Yoshihiro Hotta,* Mutsuko Hayakawa,* Takuro Fujimaki,* Misako Takeda,* Yasushi Isashiki, Norio Ohba and Atsushi Kanai* *Department

More information

Variant interpretation exercise. ACGS Somatic Variant Interpretation Workshop Joanne Mason 21/09/18

Variant interpretation exercise. ACGS Somatic Variant Interpretation Workshop Joanne Mason 21/09/18 Variant interpretation exercise ACGS Somatic Variant Interpretation Workshop Joanne Mason 21/09/18 Format of exercise Compile a list of tricky variants across solid cancer and haematological malignancy.

More information

Supplementary Table e1. Clinical and genetic data on the 37 participants from the WUSM

Supplementary Table e1. Clinical and genetic data on the 37 participants from the WUSM Supplementary Data Supplementary Table e1. Clinical and genetic data on the 37 participants from the WUSM cohort. Supplementary Table e2. Specificity, sensitivity and unadjusted ORs for glioma in participants

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Voretigene Neparvovec-rzyl (Luxturna) File Name: Origination: Last CAP Review: Next CAP Review: Last Review: voretigene_neparvovec_rzyl_luxturna 1/2018 N/A 6/2018 2/2018 Description

More information

Genotype to phenotype correlations in cartilage oligomeric matrix protein associated chondrodysplasias

Genotype to phenotype correlations in cartilage oligomeric matrix protein associated chondrodysplasias (2014) 22, 1278 1282 & 2014 Macmillan Publishers Limited All rights reserved 1018-4813/14 www.nature.com/ejhg ARTICLE Genotype to phenotype correlations in cartilage oligomeric matrix protein associated

More information

SALSA MLPA KIT P060-B2 SMA

SALSA MLPA KIT P060-B2 SMA SALSA MLPA KIT P6-B2 SMA Lot 111, 511: As compared to the previous version B1 (lot 11), the 88 and 96 nt DNA Denaturation control fragments have been replaced (QDX2). Please note that, in contrast to the

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name and description (please provide any alternative names you wish listed) (A)-Testing

More information

MRC-Holland MLPA. Description version 19;

MRC-Holland MLPA. Description version 19; SALSA MLPA probemix P6-B2 SMA Lot B2-712, B2-312, B2-111, B2-511: As compared to the previous version B1 (lot B1-11), the 88 and 96 nt DNA Denaturation control fragments have been replaced (QDX2). SPINAL

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Parkinson disease 8, automsomal dominant OMIM number for disease 607060 Disease

More information

MRC-Holland MLPA. Description version 08; 30 March 2015

MRC-Holland MLPA. Description version 08; 30 March 2015 SALSA MLPA probemix P351-C1 / P352-D1 PKD1-PKD2 P351-C1 lot C1-0914: as compared to the previous version B2 lot B2-0511 one target probe has been removed and three reference probes have been replaced.

More information

MRC-Holland MLPA. Description version 30; 06 June 2017

MRC-Holland MLPA. Description version 30; 06 June 2017 SALSA MLPA probemix P081-C1/P082-C1 NF1 P081 Lot C1-0517, C1-0114. As compared to the previous B2 version (lot B2-0813, B2-0912), 11 target probes are replaced or added, and 10 new reference probes are

More information

CHROMOSOMAL MICROARRAY (CGH+SNP)

CHROMOSOMAL MICROARRAY (CGH+SNP) Chromosome imbalances are a significant cause of developmental delay, mental retardation, autism spectrum disorders, dysmorphic features and/or birth defects. The imbalance of genetic material may be due

More information

Retinitis pigmentosa (RP) is an inherited dystrophic

Retinitis pigmentosa (RP) is an inherited dystrophic Genes and Mutations Causing Autosomal Dominant Retinitis Pigmentosa Stephen P. Daiger, Sara J. Bowne, and Lori S. Sullivan Human Genetics Center, School of Public Health, The University of Texas Health

More information

MRC-Holland MLPA. Description version 14; 28 September 2016

MRC-Holland MLPA. Description version 14; 28 September 2016 SALSA MLPA probemix P279-B3 CACNA1A Lot B3-0816. As compared to version B2 (lot B2-1012), one reference probe has been replaced and the length of several probes has been adjusted. Voltage-dependent calcium

More information

Sample Test Report. Mayo Clinic GeneGuide. Report. Consumer Name DOB: 00/00/0000

Sample Test Report. Mayo Clinic GeneGuide. Report. Consumer Name DOB: 00/00/0000 Mayo Clinic GeneGuide Report Consumer Name DOB: // Table Of Contents Mayo Clinic GeneGuide Genetic Test Results Demographics and Ordering Information 3 How to Use This Report 4 Carrier Screening - No variants

More information

MRC-Holland MLPA. Description version 07; 26 November 2015

MRC-Holland MLPA. Description version 07; 26 November 2015 SALSA MLPA probemix P266-B1 CLCNKB Lot B1-0415, B1-0911. As compared to version A1 (lot A1-0908), one target probe for CLCNKB (exon 11) has been replaced. In addition, one reference probe has been replaced

More information

Retinal dystrophies, genomic applications in diagnosis and prospects for therapy

Retinal dystrophies, genomic applications in diagnosis and prospects for therapy Review Article Retinal dystrophies, genomic applications in diagnosis and prospects for therapy Benjamin M. Nash 1,2,3, Dale C. Wright 2,3, John R. Grigg 1, Bruce Bennetts 2,3, Robyn V. Jamieson 1,3 1

More information

Supplemental material Mutant DNMT3A: A Marker of Poor Prognosis in Acute Myeloid Leukemia Ana Flávia Tibúrcio Ribeiro, Marta Pratcorona, Claudia

Supplemental material Mutant DNMT3A: A Marker of Poor Prognosis in Acute Myeloid Leukemia Ana Flávia Tibúrcio Ribeiro, Marta Pratcorona, Claudia Supplemental material Mutant DNMT3A: A Marker of Poor Prognosis in Acute Myeloid Leukemia Ana Flávia Tibúrcio Ribeiro, Marta Pratcorona, Claudia Erpelinck-Verschueren, Veronika Rockova, Mathijs Sanders,

More information

A guide to understanding variant classification

A guide to understanding variant classification White paper A guide to understanding variant classification In a diagnostic setting, variant classification forms the basis for clinical judgment, making proper classification of variants critical to your

More information

Abstract. Optimization strategy of Copy Number Variant calling using Multiplicom solutions APPLICATION NOTE. Introduction

Abstract. Optimization strategy of Copy Number Variant calling using Multiplicom solutions APPLICATION NOTE. Introduction Optimization strategy of Copy Number Variant calling using Multiplicom solutions Michael Vyverman, PhD; Laura Standaert, PhD and Wouter Bossuyt, PhD Abstract Copy number variations (CNVs) represent a significant

More information

Novel Heterozygous Mutation in YAP1 in A Family with Isolated Ocular Colobomas

Novel Heterozygous Mutation in YAP1 in A Family with Isolated Ocular Colobomas Novel Heterozygous Mutation in YAP1 in A Family with Isolated Ocular Colobomas Julius T. Oatts 1, Sarah Hull 2, Michel Michaelides 2, Gavin Arno 2, Andrew R. Webster 2*, Anthony T. Moore 1,2* 1. Department

More information

Global variation in copy number in the human genome

Global variation in copy number in the human genome Global variation in copy number in the human genome Redon et. al. Nature 444:444-454 (2006) 12.03.2007 Tarmo Puurand Study 270 individuals (HapMap collection) Affymetrix 500K Whole Genome TilePath (WGTP)

More information

Improving detection and genetic counseling in carriers of spinal muscular atrophy

Improving detection and genetic counseling in carriers of spinal muscular atrophy Clin Genet 2014: 85: 470 475 Printed in Singapore. All rights reserved Short Report 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd CLINICAL GENETICS doi: 10.1111/cge.12222 Improving detection

More information

C horoideraemia is an X linked, recessively inherited,

C horoideraemia is an X linked, recessively inherited, 658 CLINICAL SCIENCE Retrospective, longitudinal, and cross sectional study of visual acuity impairment in choroideraemia M Flynn Roberts, G A Fishman, D K Roberts, J R Heckenlively, R G Weleber, R J Anderson,

More information

Research Article Retinitis Pigmentosa with EYS Mutations Is the Most Prevalent Inherited Retinal Dystrophy in Japanese Populations

Research Article Retinitis Pigmentosa with EYS Mutations Is the Most Prevalent Inherited Retinal Dystrophy in Japanese Populations Journal of Ophthalmology Volume 2015, Article ID 819760, 10 pages http://dx.doi.org/10.1155/2015/819760 Research Article Retinitis Pigmentosa with EYS Mutations Is the Most Prevalent Inherited Retinal

More information

Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes

Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes KM Kortüm 1,8 *, EK Mai 3,4 *, NH Hanafiah 3 *, CX Shi 1, YX Zhu 1, L Bruins 1, S Barrio 1,

More information

Cytogenetics 101: Clinical Research and Molecular Genetic Technologies

Cytogenetics 101: Clinical Research and Molecular Genetic Technologies Cytogenetics 101: Clinical Research and Molecular Genetic Technologies Topics for Today s Presentation 1 Classical vs Molecular Cytogenetics 2 What acgh? 3 What is FISH? 4 What is NGS? 5 How can these

More information

MRC-Holland MLPA. Description version 29; 31 July 2015

MRC-Holland MLPA. Description version 29; 31 July 2015 SALSA MLPA probemix P081-C1/P082-C1 NF1 P081 Lot C1-0114. As compared to the previous B2 version (lot 0813 and 0912), 11 target probes are replaced or added, and 10 new reference probes are included. P082

More information

MRC-Holland MLPA. Description version 08; 18 November 2016

MRC-Holland MLPA. Description version 08; 18 November 2016 SALSA MLPA probemix P122-D1 NF1 AREA Lot D1-1016. As compared to lot C2-0312, four probes in the NF1 area and one reference probe have been removed, four reference probes have been replaced and several

More information

Most severely affected will be the probe for exon 15. Please keep an eye on the D-fragments (especially the 96 nt fragment).

Most severely affected will be the probe for exon 15. Please keep an eye on the D-fragments (especially the 96 nt fragment). SALSA MLPA probemix P343-C3 Autism-1 Lot C3-1016. As compared to version C2 (lot C2-0312) five reference probes have been replaced, one reference probe added and several lengths have been adjusted. Warning:

More information

Exceptional progress has been made during the past two decades in identifying genes

Exceptional progress has been made during the past two decades in identifying genes SPECIAL ARTICLE Perspective on Genes and Mutations Causing Retinitis Pigmentosa Stephen P. Daiger, PhD; Sara J. Bowne, PhD; Lori S. Sullivan, PhD Exceptional progress has been made during the past two

More information

CHAPTER IV RESULTS Microcephaly General description

CHAPTER IV RESULTS Microcephaly General description 47 CHAPTER IV RESULTS 4.1. Microcephaly 4.1.1. General description This study found that from a previous study of 527 individuals with MR, 48 (23 female and 25 male) unrelated individuals were identified

More information

Advances in genetic diagnosis of neurological disorders

Advances in genetic diagnosis of neurological disorders Acta Neurol Scand 2014: 129 (Suppl. 198): 20 25 DOI: 10.1111/ane.12232 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd ACTA NEUROLOGICA SCANDINAVICA Review Article Advances in genetic diagnosis

More information

TP53 mutational profile in CLL : A retrospective study of the FILO group.

TP53 mutational profile in CLL : A retrospective study of the FILO group. TP53 mutational profile in CLL : A retrospective study of the FILO group. Fanny Baran-Marszak Hopital Avicenne Bobigny France 2nd ERIC workshop on TP53 analysis in CLL, Stresa 2017 TP53 abnormalities :

More information

SALSA MLPA probemix P241-D2 MODY mix 1 Lot D As compared to version D1 (lot D1-0911), one reference probe has been replaced.

SALSA MLPA probemix P241-D2 MODY mix 1 Lot D As compared to version D1 (lot D1-0911), one reference probe has been replaced. mix P241-D2 MODY mix 1 Lot D2-0413. As compared to version D1 (lot D1-0911), one reference has been replaced. Maturity-Onset Diabetes of the Young (MODY) is a distinct form of non insulin-dependent diabetes

More information

CentoXome FUTURE'S KNOWLEDGE APPLIED TODAY

CentoXome FUTURE'S KNOWLEDGE APPLIED TODAY CentoXome FUTURE'S KNOWLEDGE APPLIED TODAY More genetic information requires cutting-edge interpretation techniques Whole Exome Sequencing For certain patients the combination of symptoms does not allow

More information

SNP Array NOTE: THIS IS A SAMPLE REPORT AND MAY NOT REFLECT ACTUAL PATIENT DATA. FORMAT AND/OR CONTENT MAY BE UPDATED PERIODICALLY.

SNP Array NOTE: THIS IS A SAMPLE REPORT AND MAY NOT REFLECT ACTUAL PATIENT DATA. FORMAT AND/OR CONTENT MAY BE UPDATED PERIODICALLY. SAMPLE REPORT SNP Array NOTE: THIS IS A SAMPLE REPORT AND MAY NOT REFLECT ACTUAL PATIENT DATA. FORMAT AND/OR CONTENT MAY BE UPDATED PERIODICALLY. RESULTS SNP Array Copy Number Variations Result: LOSS,

More information

Advance Your Genomic Research Using Targeted Resequencing with SeqCap EZ Library

Advance Your Genomic Research Using Targeted Resequencing with SeqCap EZ Library Advance Your Genomic Research Using Targeted Resequencing with SeqCap EZ Library Marilou Wijdicks International Product Manager Research For Life Science Research Only. Not for Use in Diagnostic Procedures.

More information

Intron p Hybrid with p.leu245val p. Gly336Cys. p.leu62phe p. Ala137Val p. Asn152Thr hybrid with p.leu245val p.

Intron p Hybrid with p.leu245val p. Gly336Cys. p.leu62phe p. Ala137Val p. Asn152Thr hybrid with p.leu245val p. RHD negative, i.e. null Phenotype Allele name Nucleotide change Exon Predicted amino acid change D RHD*01N.01 RHD deletion 1-10 p.0 Allele name detail Comments D RHD*08N.01 RHD*Pseudogene RHD* Ψ 37- bp

More information

MRC-Holland MLPA. Description version 12; 13 January 2017

MRC-Holland MLPA. Description version 12; 13 January 2017 SALSA MLPA probemix P219-B3 PAX6 Lot B3-0915: Compared to version B2 (lot B2-1111) two reference probes have been replaced and one additional reference probe has been added. In addition, one flanking probe

More information

Next generation sequencing identified novel heterozygous nonsense mutation in CNGB1 gene associated with retinitis pigmentosa in a Chinese patient

Next generation sequencing identified novel heterozygous nonsense mutation in CNGB1 gene associated with retinitis pigmentosa in a Chinese patient /, 2017, Vol. 8, (No.51), pp: 88345-88350 Next generation sequencing identified novel heterozygous nonsense mutation in CNGB1 gene associated with retinitis pigmentosa in a Chinese patient Santasree Banerjee

More information

MRC-Holland MLPA. Description version 29;

MRC-Holland MLPA. Description version 29; SALSA MLPA KIT P003-B1 MLH1/MSH2 Lot 1209, 0109. As compared to the previous lots 0307 and 1006, one MLH1 probe (exon 19) and four MSH2 probes have been replaced. In addition, one extra MSH2 exon 1 probe,

More information

SALSA MLPA probemix P185-C2 Intersex Lot C2-1015: As compared to the previous version C1 (lot C1-0611), the lengths of four probes have been adjusted.

SALSA MLPA probemix P185-C2 Intersex Lot C2-1015: As compared to the previous version C1 (lot C1-0611), the lengths of four probes have been adjusted. mix P185-C2 Intersex Lot C2-1015: As compared to the previous version C1 (lot C1-0611), the lengths of four s have been adjusted. The sex-determining region on chromosome Y (SRY) is the most important

More information

AVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits

AVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits AVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits Accelerating clinical research Next-generation sequencing (NGS) has the ability to interrogate many different genes and detect

More information

DNA-seq Bioinformatics Analysis: Copy Number Variation

DNA-seq Bioinformatics Analysis: Copy Number Variation DNA-seq Bioinformatics Analysis: Copy Number Variation Elodie Girard elodie.girard@curie.fr U900 institut Curie, INSERM, Mines ParisTech, PSL Research University Paris, France NGS Applications 5C HiC DNA-seq

More information

SALSA MLPA probemix P169-C2 HIRSCHSPRUNG-1 Lot C As compared to version C1 (lot C1-0612), the length of one probe has been adjusted.

SALSA MLPA probemix P169-C2 HIRSCHSPRUNG-1 Lot C As compared to version C1 (lot C1-0612), the length of one probe has been adjusted. mix P169-C2 HIRSCHSPRUNG-1 Lot C2-0915. As compared to version C1 (lot C1-0612), the length of one has been adjusted. Hirschsprung disease (HSCR), or aganglionic megacolon, is a congenital disorder characterised

More information

Mutational and phenotypical spectrum of phenylalanine hydroxylase deficiency in Denmark

Mutational and phenotypical spectrum of phenylalanine hydroxylase deficiency in Denmark Clin Genet 2016: 90: 247 251 Printed in Singapore. All rights reserved Short Report 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd CLINICAL GENETICS doi: 10.1111/cge.12692 Mutational and

More information

SNP Array NOTE: THIS IS A SAMPLE REPORT AND MAY NOT REFLECT ACTUAL PATIENT DATA. FORMAT AND/OR CONTENT MAY BE UPDATED PERIODICALLY.

SNP Array NOTE: THIS IS A SAMPLE REPORT AND MAY NOT REFLECT ACTUAL PATIENT DATA. FORMAT AND/OR CONTENT MAY BE UPDATED PERIODICALLY. SAMPLE REPORT SNP Array NOTE: THIS IS A SAMPLE REPORT AND MAY NOT REFLECT ACTUAL PATIENT DATA. FORMAT AND/OR CONTENT MAY BE UPDATED PERIODICALLY. RESULTS SNP Array Copy Number Variations Result: GAIN,

More information

No mutations were identified.

No mutations were identified. Hereditary High Cholesterol Test ORDERING PHYSICIAN PRIMARY CONTACT SPECIMEN Report date: Aug 1, 2017 Dr. Jenny Jones Sample Medical Group 123 Main St. Sample, CA Kelly Peters Sample Medical Group 123

More information

Hearing Loss Imaging Thyroid function tests TFT (age at test)

Hearing Loss Imaging Thyroid function tests TFT (age at test) Clinical Information on patients. Unclassified variants are denoted in brackets. EVA is enlarged vestibular aqueducts - Indicates no information. means asian. Patient TFT (age at test) 25215 c.1001+1g>a

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Invasive Prenatal (Fetal) Diagnostic Testing File Name: Origination: Last CAP Review: Next CAP Review: Last Review: invasive_prenatal_(fetal)_diagnostic_testing 12/2014 3/2018

More information

New: P077 BRCA2. This new probemix can be used to confirm results obtained with P045 BRCA2 probemix.

New: P077 BRCA2. This new probemix can be used to confirm results obtained with P045 BRCA2 probemix. SALSA MLPA KIT P045-B2 BRCA2/CHEK2 Lot 0410, 0609. As compared to version B1, four reference probes have been replaced and extra control fragments at 100 and 105 nt (X/Y specific) have been included. New:

More information

Approach to Mental Retardation and Developmental Delay. SR Ghaffari MSc MD PhD

Approach to Mental Retardation and Developmental Delay. SR Ghaffari MSc MD PhD Approach to Mental Retardation and Developmental Delay SR Ghaffari MSc MD PhD Introduction Objectives Definition of MR and DD Classification Epidemiology (prevalence, recurrence risk, ) Etiology Importance

More information

SALSA MLPA KIT P050-B2 CAH

SALSA MLPA KIT P050-B2 CAH SALSA MLPA KIT P050-B2 CAH Lot 0510, 0909, 0408: Compared to lot 0107, extra control fragments have been added at 88, 96, 100 and 105 nt. The 274 nt probe gives a higher signal in lot 0510 compared to

More information

Supplementary note: Comparison of deletion variants identified in this study and four earlier studies

Supplementary note: Comparison of deletion variants identified in this study and four earlier studies Supplementary note: Comparison of deletion variants identified in this study and four earlier studies Here we compare the results of this study to potentially overlapping results from four earlier studies

More information

22q11.2 DELETION SYNDROME. Anna Mª Cueto González Clinical Geneticist Programa de Medicina Molecular y Genética Hospital Vall d Hebrón (Barcelona)

22q11.2 DELETION SYNDROME. Anna Mª Cueto González Clinical Geneticist Programa de Medicina Molecular y Genética Hospital Vall d Hebrón (Barcelona) 22q11.2 DELETION SYNDROME Anna Mª Cueto González Clinical Geneticist Programa de Medicina Molecular y Genética Hospital Vall d Hebrón (Barcelona) Genomic disorders GENOMICS DISORDERS refers to those diseases

More information

PALB2 c g>c is. VARIANT OF UNCERTAIN SIGNIFICANCE (VUS) CGI s summary of the available evidence is in Appendices A-C.

PALB2 c g>c is. VARIANT OF UNCERTAIN SIGNIFICANCE (VUS) CGI s summary of the available evidence is in Appendices A-C. Consultation sponsor (may not be the patient): First LastName [Patient identity withheld] Date received by CGI: 2 Sept 2017 Variant Fact Checker Report ID: 0000001.5 Date Variant Fact Checker issued: 12

More information